At Ayala, we are dedicated to developing targeted therapies specifically for patients living with rare and aggressive diseases. In combination with next-generation sequencing and our proprietary bioinformatics platform, we are pioneering a novel approach to cancer treatment.
May 25, 2023
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2023
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update